PATRICK DEVAL L - 05 Jun 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 05 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 07 Jun 2024, 16:34:15 UTC
Previous filing: 19 Mar 2024
Next filing: 10 Jun 2024
SEC: View on sec.gov

Quoteable Key Fact

"PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 07 Jun 2024."

Quick Takeaways

This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 07 Jun 2024, 16:34.

What Changed

Previous filing in this sequence was filed on 19 Mar 2024.
Current net transaction value: $0.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Award		+10,461	+319%		13,743	05 Jun 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.

Content

The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.